A clinical study on CLL patients (irrespective of 17p deletion or TP53 mutation), identified no such clinical improvement in outcome between ibrutinib (n = 182, PFS 86%) and ibrutinib plus rituximab combination (n = 182, PFS 86.9%) treated groups [184,185] suggesting that addition of rituximab to ibrutinib was not associated with synergistic benefits to CLL therapy. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.